Martinez Yolanda V, Renom-Guiteras Anna, Reeves David, Erandie Ediriweera de Silva R, Esmail Aneez, Kunnamo Ilkka, Rieckert Anja, Sommerauer Christina, Sönnichsen Andreas
NIHR School for Primary Care Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, England, UK.
Institute of General Practice and Family Medicine, Witten/Herdecke University, Witten, Germany.
BMC Geriatr. 2017 Oct 16;17(Suppl 1):231. doi: 10.1186/s12877-017-0570-9.
Multimorbidity and polypharmacy are common in older people. Assessment tools or lists of criteria aimed at supporting prescription decisions for older people exist, but have often been based on expert opinion with insufficient consideration of the evidence available. The present paper describes the methods we are using to systematically review the existing evidence on the efficacy and safety of the most commonly prescribed drugs for older people in the management of their chronic medical conditions and to develop recommendations to reduce inappropriate prescriptions for incorporation into the Comprehensive Medication Review (CMR) tool developed by the PRIMA-eDS European project.
We selected the 20 most relevant drugs/drug classes in terms of prescription volumes and risk of hospitalisation for older people and the most relevant indications for the most common chronic conditions among older people and a total of 35 distinct drug-indication pairs were chosen. Based on clinical considerations we collapsed some indications together, reducing the 35 pairs to a final total of 22 separate systematic reviews (SR). A common methodology will be used for each individual SR, based on the methodological manuals of the Cochrane collaboration and the PRISMA statement for reporting systematic reviews. Our search strategy will have a staged approach where we initially search for systematic reviews and meta-analyses, but if relevant reviews are not found, then search for individual studies (controlled intervention and observational studies). Our pilot work and initial scoping of the literature suggested that very few, relevant individual trials or existing systematic reviews have researched or reported exclusively on older people. Therefore, sufficient data might not be available to perform meta-analysis but we will provide a narrative synthesis describing characteristics and findings of included studies. The collected evidence will be used to construct recommendations on when not to use or to discontinue a drug, or when to reduce its dose. Recommendations will be developed in team meetings using the GRADE methodology to reflect the strength of the recommendation and the quality of the evidence. Recommendations will be built into the CMR tool.
This protocol has been prepared for a series of systematic reviews which will provide research-based evidence to develop recommendations to reduce inappropriate polypharmacy in older people as part of the CMR tool of the PRIMA-eDS project.
多病共存和多重用药在老年人中很常见。虽然存在旨在支持老年人处方决策的评估工具或标准清单,但这些通常基于专家意见,对现有证据的考虑不足。本文描述了我们正在使用的方法,以系统地回顾关于老年人最常用药物在治疗慢性疾病方面的疗效和安全性的现有证据,并制定建议以减少不适当的处方,纳入由PRIMA-eDS欧洲项目开发的综合药物审查(CMR)工具。
我们根据老年人的处方量和住院风险选择了20种最相关的药物/药物类别,以及老年人中最常见慢性病的最相关适应症,共选择了35个不同的药物-适应症对。基于临床考虑,我们将一些适应症合并在一起,将35对减少到最终总共22项独立的系统评价(SR)。将根据Cochrane协作组织的方法手册和报告系统评价的PRISMA声明,对每个单独的SR使用通用方法。我们的检索策略将采用分阶段方法,首先检索系统评价和荟萃分析,但如果未找到相关评价,则检索个体研究(对照干预和观察性研究)。我们的试点工作和文献初步范围界定表明,很少有相关的个体试验或现有系统评价专门针对老年人进行研究或报告。因此,可能没有足够的数据进行荟萃分析,但我们将提供叙述性综述,描述纳入研究的特征和结果。收集到的证据将用于构建关于何时不使用或停用药物、何时减少药物剂量的建议。将在团队会议上使用GRADE方法制定建议,以反映建议的强度和证据的质量。建议将纳入CMR工具。
本方案是为一系列系统评价制定的,这些系统评价将提供基于研究的证据,以制定建议,减少老年人中不适当的多重用药,作为PRIMA-eDS项目CMR工具的一部分。